Open AccessCOMPARISON OF ZIDOVUDINE COMBINATION AND TENOFOVIR COMBINATION ON THE EFFECTIVENESS OF THERAPY AND SIDE EFFECTS IN HIV/AIDS PATIENTS IN RSAL MINTOHARDJO
Author(s) -
Phihaniar Insaniputri,
Sudibyo Supardi,
Retnosari Andrajati
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10s5.23107
Subject(s) - zidovudine , medicine , stavudine , regimen , lamivudine , combination therapy , tenofovir , incidence (geometry) , human immunodeficiency virus (hiv) , virology , viral disease , virus , hepatitis b virus , physics , optics
Objectives: Tenofovir-based therapy is a newly adopted first-line HIV/AIDS therapy regimen in Indonesia that is replacing the stavudine-based regimen. However, zidovudine-based regimens remain the first-line therapy for patients with HIV/AIDS. This study aimed to compare the effectiveness and incidence of adverse effects with hemoglobin (Hb) in both zidovudine- and tenofovir-based regimens in HIV/AIDS patients at Mintohardjo Hospital. Methods: We used a cross-sectional comparative research design. The data analyzed were medical records of all HIV/AIDS patients treated through 2015. Results: The sample included 75 patients in the zidovudine group and 53 patients in the tenofovir group. Wilcoxon signed-rank tests indicated that both combinations of therapy were effective in improving CD4+ cells. Initial CD4+ cell counts ≤ 200 cells/mm3 were 4.55 times better at increasing CD4+ cell counts when compared with an initial CD4+ > 200 cells/mm3. Chi-square results showed that both treatment combinations affected the decrease in Hb. Patients using the zidovudine combination had 4.59 times greater risk for a Hb decrease compared with the tenofovir combination. Conclusions: Zidovudine- and tenofovir-based regimens had similar effectiveness in increasing CD4+ cell counts, but the tendency to cause anemia in tenofovir-based regimens was less than that of the zidovudine-based regimens.